Skip to main content
GALECTIN THERAPEUTICS INC logo

GALECTIN THERAPEUTICS INC — Investor Relations & Filings

Ticker · GALT ISIN · US3632252025 LEI · 5299004HFYSAZM2ALW85 US Manufacturing
Open in API
Filings indexed 1,091 across all filing types
Latest filing 2011-03-09 Director's Dealing
Country US United States of America
Listing US GALT

About GALECTIN THERAPEUTICS INC

https://galectintherapeutics.com/

Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for fibrotic diseases, chronic liver disease, and cancer. The company's therapeutic approach centers on inhibiting the galectin-3 protein, which is implicated in various inflammatory, fibrotic, and malignant conditions. Its lead drug candidate, belapectin (GR-MD-02), is a proprietary carbohydrate-based drug designed to bind to and inhibit galectin-3. The primary development program for belapectin is focused on treating non-alcoholic steatohepatitis (MASH) with cirrhosis, a serious liver disease with no currently approved therapies.

Recent filings

Filing Released Lang Actions
4 Filing
Director's Dealing
2011-03-09 English
8-K Filing
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is used for current reports on significant events. The content focuses on the appointment of a new CEO and the granting of stock options, which are changes in senior management and related compensation arrangements. There is no detailed financial data or comprehensive report content, but rather an announcement of management changes and related agreements. This fits the category of Board/Management Information (MANG). The document length is 4575 characters, which is consistent with a typical 8-K filing for management changes. Therefore, the classification is MANG with high confidence.
2011-03-09 English
8-K Filing
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The content includes an announcement of receiving the final tranche of federal grant funding and an update on the company's cash position. It references a news release attached as Exhibit 99.1. The document does not contain detailed financial statements or comprehensive financial analysis, but rather a brief update on financing and cash position. This fits the category of Capital/Financing Update (CAP), as it relates to funding and cash position updates. The document length is 3363 characters, which is short and consistent with an announcement rather than a full report. Therefore, the classification is CAP with high confidence.
2011-02-10 English
8-K Filing
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content details an agreement related to amendments to preferred stock and warrants, including changes to the Certificate of Designation and warrant terms. It includes references to exhibits with legal agreements and amended certificates. There are no financial statements or quarterly/yearly financial results presented, nor is this a proxy or voting result announcement. The document is not a full annual or interim report, nor an earnings release. It is a regulatory filing disclosing a material definitive agreement and amendments to corporate governance documents. Therefore, the appropriate classification is Regulatory Filings (RNS).
2011-01-27 English
8-K Filing
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content specifically discusses the entry into material definitive agreements related to the sale of Series C Preferred Stock and unregistered sales of equity securities. It includes details about subscription agreements and certificates of designation, which are typical disclosures in a capital raising or financing context. There is no indication of full financial statements or comprehensive financial performance data, so it is not an Annual Report (10-K) or Interim Report (IR). The document is not a proxy, earnings release, or management discussion. The primary focus is on financing activities and capital structure changes. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is sufficient and contains substantive information about the financing event, not just an announcement of a report, so it is not RPA or RNS. Confidence is high given the clear description of financing transactions.
2011-01-14 English
D Filing
Regulatory Filings
2011-01-12 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.